obviously ur no expert so stick to what you do know which is very little. The original intake group had severely advanced MF patients that had exhausted all other possible options. Nothing else worked for them. For IMET to get CI & CR from this group speaks highly of it's efficacy. Many of these patients had gone off of Jakafi as a failred therapy. If MAYO hand picked healthier patients from the get go results would have been far higher, however Teferri is into saving lives and gave these people another chance at a longer life.
IMET has far less side effects than INCY's Jakafi which offers no CR and relieves spleen swelling for several months till patients finally succumb to its side effects and choose to stop treatment or expire altogether. Hardly a comparative, yet INCY has FDA approval because there was nothing else around bfr IMETand has made billions on it.
E2 mentioned he was concerned about Teferri not being scheduled yet at the ASH, but until the FDA hold on IMET's clinical hold is lifted he's limited to what he can present other than updated data from the MF trials.
we'll need something more before ASH to keep the sharks at bay, otherwise they'll eat through the haul of this ship
not sure when he was scheduled last year, but he did blurt out some news on Imet bfr the conference, much to everyone's surprise. With all the politics & lobbying surrounding this potential blockbuster they've probably adapted a more reserved stance. If the MAYO wasn't behind IMET they would have never published IMET as one of their on going MF programs offered in their latest brochure.
Company CC on Aug 11 is to discuss "recent events" may be just for the Asterias shares, but could be for much bigger news yet to come.
Watch out for icebergs!
Sure your breakout line hasn't become the breakdown line?
Short numbers updated;
07/15/2014 23,241,483 up 4.95% Av vol 3,000,162
06/30/2014 22,145,438 down(13.11%) Av vol 5,319,798
although av vol has decreased by 2.3mil per day short interest has increased by 1.1 mil shares.
My guess is that with last weeks take down short interest has increased since
....what possible catalysts prior to Nov.? The hedge fund shorts are all over this "quiet time" period lapse. Nov is not soon enough.
B) FDA release on hold?
C) MAYO expanding it's study on IMET?
Hydroxyurea can cause a severe decrease in the number of blood cells in your bone marrow. This may cause certain symptoms like neutropenia and may increase the risk that you will develop a serious infection or bleeding. Hydroxyurea even with a 30% response rate it's side effects still beg for other safer far less dangerous alternatives. With Jakafi sharing similar side effects and only a 13% improvement over hydroxyurea the case for IMET has just received another boost from this failed study.
How does INCY claim it's drug is approve-able in PV based on a failed statistical significant trial? Why don't they need FDA approval for PV? The drug has many severe side effects. Where are the ambulance chasers?
Marcia, Marcia, Marcia the INCY results just underscore that Jakafi does not work. The market makers are well aware of the potential in IMET hence the manipulated trade activity. This news should have been a huge boost in SP to GERN today yet SP was taken down AGAIN!
Jakafi, the $1billion placebo.
Much of what we see in manipulated trading and FDA actions or lack of can easily be pointed to the INCY lobby, hell bent on protecting their threatened market niche. The drug obviously has very limited use and it's efficacy is questionable yet it has been grandfathered in under no other treatment available fast tracked designation, a status that has not been questioned until Jakafi met IMET. Hands down IMET has proven efficacy and needs to be developed for the greater good of all MF, PV and ET patients.
MM certainly gets it. Look at ASTYV today. 30% drop on only 13,659 vol. GERN's two week trading pattern hasn't faired much better...on what bad news? GAP filled. IBB index has recovered. Yet SP languishes, This is being totally manipulated downwards. Without an update on clinical trials from the company or a clinical lift from the FDA, SP will continue to take such abuse.
What's your prediction Blazer on how low these wall street mouth foaming hedge funds take down the SP before they decide to cover? We're already down to pre-partial lift MAYO news release levels.